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A B S T R A C T
Providing information about substances injected can reduce the negative impact of illicit drug consumption and
support people who inject drugs to make informed decisions. In Australia, information about drugs injected
relies largely on periodic self-report surveys. For the first time, the analysis of the residual content of used
injecting equipment was conducted in a supervised injecting facility (SIF) located in Sydney, Australia.
The aim was to gain a better understanding of the substances injected by clients through: (1) chemical
analyses of the content of used syringes; (2) comparison of these results with clients' self-reported drug use; and
(3) assessing the usefulness of analysing other injecting equipment to detect substances used.
During one week in February 2019, syringes and other injecting equipment were collected at the Sydney SIF.
Their residual content was analysed by gas-chromatography/mass-spectrometry. Heroin was the most commonly
detected substance (present in 51% of syringes), followed by methamphetamine (22%) and oxycodone (10%). In
addition to the main psychoactive substance, cutting agents reported in the literature were also detected in used
syringes. The main psychoactive substance identified by laboratory analysis reliably corresponded with users'
self-reported drug type.
Analytical confirmation of substances injected allows for the provision of better targeted harm reduction
messaging based on timely and objective data. The approach used is amenable to clients and feasible in the
Australian SIF context. Upscaling and wider implementation could be done through Needle and Syringe
Programs, and would support the early detection of harmful substances entering drug markets and better inform
harm reduction strategies.
1. Introduction
Drug injection is associated with considerable mortality and mor-
bidity due to overdose and infectious disease (Des Jarlais et al., 2005;
Mathers et al., 2013). Australia’s National Drug Strategy encompasses
three pillars – demand reduction, supply reduction and harm reduction
(Dolan et al., 2005). Harm reduction aims to reduce the negative impact
of drug consumption by providing clean injecting equipment and
specific risk advice, supportive environments (e.g. supervised injecting
centres) and reducing risks.
Providing information about substances injected by people who
inject drugs (PWID) in Australia currently relies on periodic self-report
surveys (Iversen et al., 2017; Peacock et al., 2018). While results from
these surveys are most informative, the methodology does not allow
results to be confirmed analytically. Furthermore, the surveys rely on
users’ perceptions of the drug injected and their willingness to report
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the information (Evrard et al., 2010). Even if the main psychoactive
substance is known to PWID, the presence of cutting agents are gen-
erally unknown or not reported (Broséus et al., 2015).
Chemical analysis of the residual content of used syringes provides
important objective and complementary information about the sub-
stances injected. This knowledge allows better targeted harm reduction
information and supports PWID to make informed decisions. However,
to our knowledge, no such studies have been undertaken in Australian
settings.
Since 2016, several European studies have already implemented this
approach (Lefrançois et al., 2017, 2016; Néfau et al., 2015; Péterfi
et al., 2016, 2014). The European Monitoring Centre for Drugs and
Drugs addiction (EMCDDA) published a study entitled drugs in syringes
from six European cities (Amsterdam, Budapest, Glasgow, Helsinki,
Lausanne, Paris) (EMCDDA, 2019). Results show that consumption
trends are different in neighboring European cities and at that time no
fentanyl or analogues were detected. Meanwhile in North America,
Blachman-Forshay et al. (2018) conducted a similar study and reported
the presence of fentanyl and analogues in 17% of syringes collected.
The success of these studies in Europe and North America inspired the
actual study conducted at the Uniting Medically Supervised Injecting
Centre in Sydney (Sydney SIF).
The Sydney SIF was established in Sydney in 2001 in response to the
high rates of overdose and ambulance call outs in the vicinity. At the
Sydney SIF, trained staff (nurses and health education officers), provide
a low threshold and non-judgmental space, clean injecting equipment,
supervision of injection episodes, overdose management and referral to
a range of health and social services (Latimer et al., 2016). The Sydney
SIF has approximately 16,500 registered clients, has supervised more
than one million injections and successfully managed almost 8500
opioid overdoses (Uniting Medically Supervised Injecting Centre MSIC,
2019).
In this study we aimed to develop a better understanding of all
substances injected by clients of the Sydney SIF by: (1) conducting
chemical analyses of the content of used syringes and other injecting
equipment; (2) comparing the results with self-reported drug type; and
(3) assessing the usefulness of analysing other injecting equipment to
detect substances used.
2. Materials and method
2.1. Design
During a seven-day period in February 2019, all used injecting
equipment was retrieved from randomly selected disposal bins. The
Sydney SIF has eight injecting booths where each booth can seats up to
two people and contains one syringe disposal (‘fit’) bin. For each clients’
visit, specific information is routinely recorded, including the substance
the client intends to inject, the number of the booth they use for in-
jection and other events that occur during the visit, including the nature
and management of onsite overdoses. As the service routinely collects
self-reported data on drugs injected, it is a unique source of real-time
self-report drug trend information that can be compared to the chemical
analysis of used syringes.
Once collected, the residual drug content of the used equipment was
analysed by gas-chromatography/mass-spectrometry. The results were
then compared to the substance self-reported by clients during the same
time period.
All participants were informed of the voluntary and anonymous
nature of the study and consented to the inclusion of their data. They
were also informed that it was not possible to link the analytical results
to an individual. An opt-out approach to consent was utilised whereby
participants’ used injecting equipment was included in the research
unless they requested otherwise. If a client wished to be excluded, they
informed staff and were directed to one of the remaining seven booths
which were not being used for the study. The study had overwhelming
support from clients and was informed and supported by the Sydney SIF
Consumer Action Group. Ethics approval was obtained (ETH18-2295,
University of Technology Sydney, Human Research Ethics Committee).
2.2. Sampling procedure
Syringes and other injecting equipment disposed of in syringe dis-
posal bins were collected every day for a period of seven days from a
randomly selected booth. The booth where the collection of used
equipment occurred was randomly selected each day and was only
known to staff (so client choice of booth was not influenced by the
study). At the end of each day or when the syringe disposal bin was full,
the bin was labelled with the date, time of collection, and booth number
and put aside by clinical staff. The bins were then transported second-
daily to the University of Technology Sydney (UTS) for analysis.
2.3. Chemical analysis
2.3.1. Chemicals and standards
Certified reference materials of the most common target compounds
(psychoactive substances and cutting agents) were purchased from
Novachem (Collingwood, VIC, Australia). Mephedrone,
Methamphetamine, Cocaine, Fentanyl, Oxycodone, Buprenorphine,
Phenobarbital, Paracetamol, Caffeine, Levamisole, Phenacetin,
Morphine, Codeine, Diacetylmorphine and Methamphetamine-D5 were
obtained as 1000 ppm methanolic solutions. Carfentanil, Ocfentanyl,
Furanylfentanyl were obtained as 100 ppm methanolic solution. A
mixture of phenazine (50 ppm) and methamphetamine-D5 (20 ppm)
was used as the Internal Standard (IS). Liquid chromatography-mass
spectrometry (LC–MS) grade methanol (MeOH) and ethyl acetate
(EtAC) were purchased from ChemSupply (Gillman, SA, Australia).
MEOH was used for extraction and a mixture of MEOH and EtAC was
used as Gas-Chromatography/Mass Spectrometry (GC–MS) washes.
2.3.2. Sample preparation and instrumental analysis
The sample preparation and analysis occurred at UTS and followed
the procedure published by Lefrançois et al., 2016 based on toxicology
literature (Maurer, 2005; Pfleger et al., 1992). In short, syringe disposal
bins were emptied and injecting equipment were separated according
to their type (i.e. syringes, spoons, concealment bags and filters). The
residual content of used injecting equipment was extracted with one
milliliter of methanol (the syringes were filled and emptied five times,
spoons and concealment bags were filled up with methanol, and filters
were soaked in 1 ml of MeOH for one minute). Once the extraction was
done, 250 μl methanolic extract was filtered into a GC–MS vial. 50 μl of
IS was added and one microliter was analysed by GC–MS. Separation
was obtained with a HP-5 ms capillary column (30 m length, 0.25 mm
in diameter and 0.25 um film thickness). Splitless mode was used, with
an inlet temperature of 270 °C, and an oven temperature program in-
creasing from 70 °C to 320 °C for a total run time of 31 min. This
analytical method was previously validated (Lefrançois et al., 2016)
and followed a general unknown screening approach that includes a
large variety of substances registered in commercial libraries. The list of
compounds screened for can be found in (EMCDDA, 2019).
2.3.3. Data treatment and statistical analysis
After analysis, total ion chromatogram visualisation and peak area
integration were performed on the MSD Enhanced ChemStation soft-
ware. Library search was performed with several commercial libraries
(Maurer, Pfleger, Weber library, PMW_3 acronym; National Institute of
Standards and Technology, NIST17 and Wiley Mass Spectra of Designer
Drugs 2019 DDdrugs). When a peak was characterised by the com-
mercial libraries and if a standard was available, a standard stock so-
lution was injected to confirm the compound presence based on the
retention time and mass spectra comparison. For all compounds char-
acterised, peak areas were integrated. Limit of quantification (LOQ) for
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a standard stock solution was determined to be 5 ppm. When a peak
integration (normalized by IS) was lower than the LOQ, the result was
not considered.
Based on a combination of legal (UNODC, 2019a) and chemical
status, identified compounds were grouped into two categories, namely
the main psychoactive substances (group A) and adulterants detected in
addition to the main psychoactive substance, usually used to either
enhance its effects or increase profits (group B). Due to different leg-
islation status, subcategories were created. In particular, the main
psychoactive substances (group A) were categorized as (group A.1.)
illicit drugs (e.g. amphetamine, cathinone, cocaine, heroin, metham-
phetamine and MDMA) and (group A.2.) prescription drugs and med-
icines (e.g. buprenorphine, methadone, fentanyl, other pharmaceutical
opioids, benzodiazepines). Adulterants (group B) included other non‐-
controlled psychoactive substances (e.g. caffeine, dimethylsulfone) and
non-psychoactive medicines (e.g. paracetamol and methenamine).
Other non-psychoactive substances (e.g. sugars, usually referred as di-
luents) were also detected but are not reported in this paper. Only
syringes that contained at least one substance were included in the data
analysis. The numerical data obtained were compiled and further
analysed using Microsoft Excel (version Microsoft Office Professional
Plus 2016) and Tableau software (version 10.4.19).
2.4. Comparison with self-reported drug use
Once laboratory analysis was completed, a comparison between the
main psychoactive substance detected and the self-reported record in
the selected booths was conducted using the Kendall rank correlation
test. Kendall rank correlation is a non-parametric hypothesis test used
to test statistical dependence based on the tau coefficient. Tau coeffi-
cient values range from 0 to 1, with higher values indicating a higher
level of agreement between self-reported and chemical results (McLeod,
2005). Comparison between the self-reported record in the selected
booth and the previous year was also performed using this statistical
test. Statistical tests were performed using R (ISBN: 3-900051-07-0. R
foundation for statistical computing, Vienne, 2015).
3. Results
3.1. Participation
During the seven days of the study in February 2019, there were a
total of 966 visits to the Sydney SIF, made by 142 individual clients to
eight different booths. Of those total visits, 118 visits were to selected
booths (chosen at random each day) where the syringe disposal bins
were being sent for analysis. All clients who attended the selected
booths in that week provided anonymised data for the study (i.e. no-
body opted out of the study). The average number of clients visiting the
Sydney SIF per day during the study period was typical of the visit
pattern generally (average number of clients visiting per day in the
previous month was n =153 and in the previous year was n=144).
3.2. Main psychoactive substances
In total, 147 syringes were retrieved from disposal bins and ana-
lysed. A main psychoactive substance (referred as group A) was de-
tected in 116 syringes (see Fig. 1). In particular, 81% of syringes
(n=95) contained at least one illicit drug (group A.1). The most com-
monly detected substance in syringes was heroin (51%; n=59), fol-
lowed by methamphetamine (22%; n=26) and its derivative. The
methamphetamine derivative detected in five syringes (4%) was char-
acterised as being N-hydroxyamphetamine 2AC (according to the
PMW_3 library) and N-methoxycarbonylamphetamine (according to the
NIST17 library, spectrum available as supplementary material; m/z:
102: 100; 45: 70; 162: 18, 56: 13).
Prescription drugs and medicines (group A.2) were detected in 19%
of used syringes (22) (Oxycodone: 10%, n=12; Buprenorphine: 4%,
n=5; Methadone: 2%, n=2; Morphine: 2%, n=2; Hydromorphone:
1%, n=1). Only four syringes contained a mixture of two substances (a
mixture of methamphetamine-heroin: 2%, n=2; a mixture of me-
thamphetamine-buprenorphine: 1%, n=1; a mixture of heroin-oxyco-
done: 1%, n=1).
3.3. Adulterants
Only three different adulterants (group B) were detected. All adul-
terants detected were in syringes containing heroin or methampheta-
mine. Caffeine was detected in 10% of syringes containing heroin (6/59
syringes) and 4% of syringes containing methamphetamine (1/26 syr-
inges). Dimethylsulfone or methylsulfonylmethane was detected in 50%
of syringes containing methamphetamine (13/26 syringes) and in 20%
of syringes containing heroin (11/59 syringes). Methenamine was de-
tected in 3% of syringes containing heroin (2/59 syringes).
3.4. Comparison with self-reported drug use
Fig. 2 compares the proportion of the main psychoactive substances
detected in used syringes (n=116) and the substances self-reported by
Sydney SIF clients at the entry to the service of the collected booths
only (n=118). Heroin was the most reported drug (by 56% of clients;
n=66), followed by methamphetamine (28%; n=33), oxycodone (7%;
n=8), buprenorphine (reported as subutex and suboxone, 6%; n=7),
methadone (syrup form, 2%; n=2) and morphine (MS Cotin, 2%;
n=2).
Kendall’s test showed that there was no statistically significant dif-
ference between the results of the chemical analyses and the self-re-
ported drug type (Kendall’s test, p-value=0.00067317<0.05, Tau=1,
methamphetamine and its derivative were grouped). In addition, self-
reported drug type during the study week on the study booth are
consistent with the yearly drug type use record (Kendall’s test, p-
value=0.000616< 0.05, Tau=0.94). A summary of self-reported drug
type is available as supplementary material.
3.5. Other injecting equipment
Injecting paraphernalia retrieved from the bins other than syringes
are represented in Fig. 3. In total, 155 other pieces of injecting para-
phenalia were analysed, including 76 spoons (68 plastic spoons, 4 metal
spoons and 4 stericups), 51 concealment bags that were in direct con-
tact with the substance/s in question (29 zip bags, 20 plastic-wrapped
drug containers and 2 aluminum foils) and 17 filters. A main psy-
choactive substance (group A) and adulterants (group B) were detected
in 94% of concealment bags, 75% of spoons and 64% of filters. For
concealment bags, heroin was detected in 30 bags, methamphetamine
in 18, a mixture of both in 2 and MDMA in one. In one of them, am-
phetamine was detected in addition to methamphetamine for the first
time during this study.
4. Discussion
Chemical analysis of used syringes was successfully conducted at the
Sydney SIF and showed that (1) adulterants not reported in the litera-
ture and occasional high potency substances were detected (2) self-re-
port drug types were consistent with results confirmed by chemical
analysis; and (3) other injecting equipment analysis brings additional
information but are not representative of Sydney SIF consumption
trends. These major findings are developed below.
4.1. Main psychoactive substances detected
4.1.1. Sydney SIF analysis
Based on this study, illicit drugs (group A.1.) remained the most
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detected substances. Among them, heroin (51%) and methampheta-
mine (22%) were the two main substances detected in syringes. While
heroin injection has been common in Australia, the injection of me-
thamphetamine is a more recent trend reported in Australia and con-
firmed by other monitoring tools (Karlsson and Burns, 2018). According
to the Illicit Drug Reporting System (IDRS), the use of methampheta-
mine as a drug of choice among PWID increased from 16% to 32% from
2010 to 2017.
In addition to methamphetamine, its derivative was also detected.
This compound was also characterised above the highest point of the
calibration curve for the methamphetamine standard (100 ppm). In the
analytical literature, it appears that the structure of methamphetamine
is re-arranged due to the high temperature reached in the inlet (i.e. 270
°C) during GC–MS analysis (Li et al., 2006; Sugie et al., 2018). To our
knowledge, N-hydroxyamphetamine 2AC or N-methox-
ycarbonylamphetamine has not been reported in the literature. How-
ever, previous studies mentioned that this phenomenon is common
during methamphetamine analysis (Andersson et al., 2007; Dujourdy
et al., 2008; Lock et al., 2007). The detection of this compound seems to
indicate that this re-arrangement only occurs when the concentration of
methamphetamine is high. This suggests that some Sydney SIF clients
might be accessing potent methamphetamine. Reportedly, the annual
median purity of analysed methamphetamine specimens has increased
from 4.4%–84% in Australia since 2007 (Australian Institute of
Criminology’s Crime Statistics, 2017). The increase of methampheta-
mine potency has its own set of risks, prevention and harm reduction
messages can include the risks associated with this higher potency.
Another finding concerns the non-medical use and injection of
prescription drugs and medicines, particularly pharmaceutical opioids.
Around 10% of syringes contained one of these substances which is
consistent with previous results from Sydney SIF clinical records re-
ported in literature (Latimer et al., 2016). In addition to the chemical
analysis, blister packs (i.e. oxycodone) were found in bins which sug-
gests that tablets were crushed and dissolved for injection purpose. It
needs to be highlighted that injecting medications intended for oral
administration puts users at higher risk of vascular complications and
infections (Roux et al., 2011), however some filtration process could
limit these effects (Steele et al., 2018).
4.1.2. International comparison
This section aimed to highlight similarities and differences between
Sydney SIF results and studies conducted in six European cities
(EMCDDA, 2019) (see Fig. 4). In addition to providing local informa-
tion on the drug market, analysis of used syringes could also be used to
compare consumption, adulterants and potency of substances across
different countries. With an expanding and diversifying global drug
market as never before (e.g. diversifying supply of stimulants, drug
trafficking on the internet), equally dynamic surveillance responses
must be available and, therefore, this is an area of growing significance
(UNODC, 2019b). In the EMCDDA study, a total of 1521 syringes were
chemically analysed and 1278 of them (84%) contained at least one
psychoactive substance. The results show a high proportion of opioids
in western European countries (heroin: Amsterdam, 95%; Glasgow,
49% and Lausanne, 36%) and stimulants in all cities ((meth)ampheta-
mine: Helsinki, 53%; cathinones: Budapest, 80% and Paris: 44%; co-
caine: Amsterdam: 43%; Glasgow: 80% and; Lausanne: 72%).
The comparison revealed that strong local variations exist.
However, some general trends can be identified: (1) heroin remains one
of the main psychoactive substances injected in western Europe and in
Sydney (2) stimulants (methamphetamine, cocaine and cathinone) de-
tected in used syringes are largely reported in all cities studied (3)
prescription drugs and medicines, particularly pharmaceutical opioids
(i.e. methadone, buprenorphine and other opioids) are detected in all
cities (except Glasgow). They represent, however, a low percentage in
all cities (less than 10%), with the exception of Helsinki (53%).
The main difference between European cities and Sydney is related
to stimulant consumption. Methamphetamine was mainly detected in
Sydney, whereas cocaine was detected in Western European cities and
cathinones in Budapest. A similar difference was reported in previous
studies (Bannwarth et al., 2019; Farrell et al., 2019).
Another main difference concerns polydrug use (i.e. presence of
multiple drugs indicating the co-use of several substances). Only four
syringes (3%) collected at Sydney SIF contained a mixture of two main
psychoactive substances while 54% of the European syringes collected
contained at least two main psychoactive substances (EMCDDA, 2019).
This result is supported by self-reported survey, where only 1% of PWID
Fig. 1. Main psychoactive substances detected in the used syringes (percentages less or equal to 1% are not reported).
Fig. 2. Proportion of psychoactive substances reported by clients during the SIF
visit and detected in syringes.
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reported injecting a mixture of drugs at the Sydney SIF in the previous
year (see supplementary material - table 1), while in Europe polydrug
use is becoming more prevalent than before (Pirona et al., 2018).
Overall, one of the main general trends concerns the high pre-
valence of injecting stimulants which was recently reported as a new
challenge due to the potential of dependence (Farrell et al., 2019). In
addition to highlighting this new phenomenon, international compar-
ison is useful to obtain an objective snapshot of the geo-spatial con-
sumption of injected drugs.
4.2. Adulterants
Based on the literature, adulterants are pharmacologically active
substances detected by forensic laboratories in illicit drugs (Broséus
et al., 2016). These types of cutting agents may be added at different
steps in the history of the illicit drug. During this study, three types of
substance that could be considered as adulterants were detected: caf-
feine, methenamine and dimethylsulfone. Adulterants were only de-
tected in syringes containing illicit drugs (group A.1).
Caffeine, as an adulterant, is generally used in heroin to lower its
Fig. 3. Injecting equipment collected. The pie charts represent the proportion of psychoactive substances detected (at least one main psychoactive substances (group
A)) in black vs no substance detected in grey. Photographs from “Injecting equipment available at the needle and syringe programs, Northern Sydney central coast
brochure, NSW Health.”
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vaporisation temperature. It is also used in cocaine, amphetamine,
methamphetamine, MDMA, as a stimulant to mimic the effects of the
main psychoactive substance (Broséus et al., 2016; Cole et al., 2010).
Although only a few serious health repercussions are reported when
caffeine is consumed in small quantities, large doses can cause con-
siderable harms (mood disturbances, induce anxiety, addictive, sleep
disturbance, increases risk of a range of health problems as cardio-
myopathies) (Cole et al., 2010).
Dimethylsulfone is a commonly reported cutting agent in metham-
phetamine seizures (Collins, 2017; Morelato, 2015). In the literature, it
has not been previously reported as being a heroin cutting agent in New
South Wales (Michelot, 2018). However, heroin containing di-
methylsulfone was recently seized by the Australian Federal Police.
Interestingly, all these seizures were of small quantity (personal com-
munication). When a cutting agent is only detected in smaller seizures,
this could indicate the addition of the cutting agent at the end of the
distribution chain, i.e. when it reaches consumers (Broséus et al., 2016,
2015; Morelato et al., 2019).
Methenamine is a medicine used for the treatment of cystitis, but to
our knowledge this substance has not been reported as an adulterant.
It is important to note that the analysed syringes contained some
blood, and that the method used for compound detection is sensitive
enough to detect traces from anterior consumption (a compound that
may have been consumed by another route rather than injection). For
example, both caffeine and methenamine can be consumed orally and
could have therefore been swallowed prior to the injection.
Finally, as adulterants are pharmacologically active substances,
their interaction with the main psychoactive substance is not pre-
dictable (Cole et al., 2011; Kudlacek et al., 2017) and the risks related
to their presence should not be underestimated. For example, the
combined use of a stimulant (i.e. caffeine) and opioid (i.e. heroin) can
influence the cardiovascular system and is associated with poorer
health outcomes (Connor et al., 2014). Moreover, adulterants used are
not intended for intravenous consumption and can be hazardous. The
potential harms linked to the consumption of dimethylsulfone are not
known.
4.3. Comparison with self-reported drugs
In total, 147 syringes were collected during the week for only 118
visits registered on the selected booth. No psychoactive substances were
detected in 21% of syringes (31), meaning that a psychoactive sub-
stance was detected in 116 syringes. At the Sydney SIF, clients may use
more than one syringe for a variety of reasons. One syringe may be used
to have a small ‘taste’ of the substance before full injection with another
syringe (consistent with overdose prevention advice); syringes may be
changed after unsuccessful attempts at venipuncture and drugs trans-
ferred from one to another, syringes may be used in the preparation of a
specialty wheel filter without containing active drugs, and even if un-
used, an opened syringe package must be disposed. All of these may
account for the difference between the number of syringes collected and
the number of visits.
Based on the results, there was a remarkable consistency between
the main psychoactive substances detected in syringes and reported by
clients. Indeed, based on Kendall rank correlation result, the main
psychoactive substance injected by clients at the Sydney SIF corre-
sponded to the substance reported being consumed. Consequently, re-
sults is a good indicator to test the reliability of self-reported surveys
and vice versa (Darke, 1998),
Considering the reliability and relative ease of impementation of
self-report surveys, the added-value of chemical analysis of used syr-
inges which requires laboratory expertise and strict safety measures
Fig. 4. European and Australian comparison – frequency of the main psychoactive substances detected on n syringes collected by city. Syringe could contain more
than one substance, therefore the total per cities exceeds 100%. The data collection for European countries was performed in 2017 while it was conducted in 2019 in
Sydney.
E. Lefrancois, et al. Drug and Alcohol Dependence 209 (2020) 107909
6
may be questioned. The benefit of chemical analysis lies in the potential
detection of more potent substances or adulterants. For example, the
presence of a more potent methamphetamine was highlighted thanks to
this analysis. This information could be used to inform PWID to use
smaller amounts and test the product before injecting an entire dose to
reduce negative effects.
Of note is the prominence of fentanyl-related overdoses in North
America and this is forecast in Australia (Latimer et al., 2016). A con-
tributing factor is the consumption of illicit drugs (i.e. heroin) cut with
potent fentanyl and its analogues (Ciccarone, 2017; Warner et al.
(2018); Tupper et al., 2018). Even though during this study fentanyl
was neither self-reported nor detected in used syringes, applying such a
method could help detect abnormal phenomena such as the situation
that North America is facing. Based on the literature, only 55% of users
were aware of the presence of fentanyl in heroin in North America
(Daniulaityte et al., 2019; Griswold et al., 2018). The presence of fen-
tanyl in heroin could therefore not appear in self-reported surveys as
the users were usually not aware of it. Fentanyl presence can, however,
be detected by chemical analysis which was highlighted by Blachman-
Forshay and colleagues (2018) through the analysis of used syringes in
the United Stated. Had this type of analysis been implemented earlier, it
may have provided early warning of fenatnyl adulturation of illict drug
supplies. Finally, if such an approach was to be periodically im-
plemented, it could provide information about potential changes in the
composition of illicit drugs available on market (e.g. more potent me-
thamphetamine).
4.4. Other injecting equipment
For the first time, we also investigated the usefulness of analysing
other injecting equipment (i.e. not just syringes). The collection and
analysis of the concealment bags for example, circumvent having to
transport sharp material. During this study, we only collected 51 con-
cealment bags compared to 116 syringes (43%). Sydney SIF clients
usually dispose of concealment bags into general waste near the staff
counter where they have access to scissors to open the bags. In addition,
a number of other reasons can explain this discrepancy, such as the use
of a single bag when people attend the service together and share a
booth, the use of tablets (i.e. prescription drugs and medicines con-
tained in blister-packs), or the use of paper to conceal the drug. Out of
the 51 bags, a main psychoactive substance was detected in 48 of them
(94%). These results show that concealment bags contained enough
material to perform the analysis and give helpful results if collected.
MDMA and amphetamine were also detected in two bags containing
methamphetamine, but were neither self-reported nor detected in used
syringes.
When syringe collection cannot be performed and concealment bags
are not available, spoons could be analysed as an alternative. However,
spoons have more chance of being contaminated due to their direct
contact with other injecting equipment within the bin. Filters were the
least effective way to detect substances in our analysis.
For long-term monitoring, collection of used injecting equipment in
a SIF when an overdose is reported could provide additional informa-
tion about the substances injected . It could highlight an unusual illicit
drug or a harmful adulterant. If the analysis is conducted system-
atically, it could provide a better understanding of any additional or
unexpected reasons why overdoses occur. Preventive and harm reduc-
tion messages could thus be adapted accordingly.
4.5. Limitations
The limitations of the analysis of the content of used syringes have
already been published elsewhere (EMCDDA, 2019; Néfau et al., 2015;
Péterfi et al., 2017) and are summarised here. In this study, it was not
possible to match the drug type self-reported by an individual to the
syringe that individual actually used. In some syringes, blood traces
were observed and the method is sensitive enough to detect very small
amounts of substances. Consequently, we cannot exclude that some
substances detected are the results of a previous consumption through
another route. This problem can be accounted for by setting an arbi-
trary threshold (e.g. anything below 10% of the mass is not reported).
During our study, in two syringes containing heroin there was a low
amount of cocaine detected. The amount of cocaine detected was esti-
mated to be lower than the limit of quantification of the cocaine cali-
bration curve (5 ppm). This low amount of cocaine was not considered
as an actual consumption during injection, but rather a contamination.
Conversely, no psychoactive substances were detected in 21% of syr-
inges. The sensitivity and nature of the analytical method applied might
not enable the detection of traces of extremely potent drugs never de-
tected before and not referenced in commercial libraries. Finally, this
study analysed only seven consecutive days-worth of used syringes from
one randomly selected injecting booth each day. This study results were
generally consistent with the trend of self-reported drug type injected at
the Sydney SIF in the past month and the past year.
5. Conclusion
For the first time in Australia, substances contained in used injecting
equipment collected in a supervised injecting facility (SIF) at Sydney
were analytically confirmed. The study found that that there was re-
markable consistency between self-report of illicit drugs procured and
main psychoactive substance detected with laboratory analysis. It also
found that alternatives to syringes may be tested and provide useful
analytical results. In addition to confirming self-reported drug type,
analysis of used syringes highlighted detection of a methamphetamine
derivative that suggests there is access to a potent methamphetamine
supply.
Other used injecting equipment (i.e. other than syringes) was also
analysed. Findings suggest however, that used syringes analysis gives
the most accurate overview of all psychoactive substances injected.
Finally, this study demonstrates that the approach used is amenable
to clients and feasible in the Australian SIF context. It may also be
applicable to other settings such as Needle and Syringe Programs
(programs which provide injecting equipment). Upscaling and wider
implementation would support the early detection of harmful sub-
stances entering drug markets and better inform harm reduction stra-
tegies.
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